OTC Watch

All stocks / ECOC

ABVC BIOPHARMA, INC. ECOC

Abvc Biopharma (ECOC): convertible notes mentioned in an 8-K in November 2026, a late 10-Q notice in May 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatCostly financingLate filing OTCIDCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
ECOMINAS CORPORATION
Market tier
OTC Pink Current
Trading status
Active
Last trade
Nov 13
Website
www.ecologycoatings.com
Source: Stockwatch, 2026-11-17

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($7,908,554)
What it means

It spends more than it earns

Under strain

The company lost $7.9 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$681,480
Net cash used in operating activities
($2,986,299)
What it means

The cash could run out soon

Under strain

It had $681,480 in the bank and used about $248,858 a month. At that pace the money lasts about 3 months unless it borrows or sells more shares.

The report says
Total assets
$21,062,203
Total liabilities
$7,764,723
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $21.1 million. Its debts and unpaid bills add up to $7.8 million. That is about $0.37 owed for every $1 owned.

What this adds up to

2 of 3 checks show strain. It spends more than it earns. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-09

Estimated float about 26,976,625 shares as of 2026-11-09: 26,976,625 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Costly financing2026-11-02

8-K filed 2026-11-02 mentions: convertible note, equity line.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Late filing2026-05-15

Filed NT 10-Q on 2026-05-15: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Shares outstanding

Source: SEC filings
2025-12-31
25.1M
2026-03-03
25.4M
2026-03-31
25.8M
2026-05-14
26.0M
2026-06-30
25.8M
2026-08-10
26.7M
2026-09-30
26.8M
2026-11-09
27.0M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 S-8REGISTRATION STATEMENT
2026-11-13 424B4PROSPECTUS SUPPLEMENT
2026-11-13 424B4PROSPECTUS SUPPLEMENT
2026-11-13 424B4PROSPECTUS SUPPLEMENT
2026-11-13 424B4PROSPECTUS SUPPLEMENT
2026-11-12 S-3/AAMENDMENT NO. 1 TO FORM S-3
2026-11-10 D
2026-11-10 10-QQUARTERLY REPORT
2026-11-02 8-KCURRENT REPORT
2026-09-29 DEF 14ADEFINITIVE PROXY STATEMENT
2026-09-11 PRER14AREVISED PRELIMINARY PROXY STATEMENT
2026-08-27 8-KCURRENT REPORT

Common questions about ECOC

Does ECOC file reports with the SEC?

Yes. Abvc Biopharma files with the SEC under company number 0001173313. The most recent filing we hold is a S-8 dated 2026-11-16.

Source record

How many ECOC shares are outstanding?

26,976,625 shares as of 2026-11-09, as reported to the SEC.

Source record

Has ECOC filed reports late?

Yes. In the last 12 months it filed 1 late-filing notice, most recently a NT 10-Q on 2026-05-15. A notice means a report was not ready on time; check whether the report followed.

Source record

Is Abvc Biopharma making money?

The company lost $7.9 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record